Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today issued the following statement after the conclusion of a meeting
of the Anesthetic and Analgesic Drug Products Advisory Committee of the
U.S. Food and Drug Administration (FDA) to discuss BRIDION
(sugammadex). BRIDION is the proposed trade name for Mercks
investigational agent for the reversal of neuromuscular blockade (NMB)
induced by rocuronium or vecuronium.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more